Breaking News, Collaborations & Alliances

Fortress’ Caelum Enters Partnership with Alexion

To advance the development of CAEL-101 for light chain (AL) amyloidosis

Fortress Biotech announced that Caelum Biosciences has signed a strategic agreement with Alexion Pharmaceuticals to advance the development of CAEL-101 for light chain (AL) amyloidosis.    CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis. AL amyloidosis is a rare systemic disorder that causes misfolded immunoglobulin light chain protein to build up in and around tiss...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters